Literature DB >> 22299059

Adoptive immunotherapy of cancer: Gene transfer of T cell specificity.

Amir A Al-Khami1, Shikhar Mehrotra, Michael I Nishimura.   

Abstract

Adoptive transfer of tumor-reactive T cells has emerged as a promising advance in tumor immunotherapy. Specifically, infusion of tumor-infiltrating lymphocytes has led to long-term objective clinical responses for patients with metastatic melanoma. Donor lymphocyte infusion is also an effective treatment of post-transplant lymphoproliferative disease. However, adoptive T cell therapy has restrictions in the isolation and expansion of antigen-specific lymphocytes for a large group of patients. One approach to circumvent this limitation and extend adoptive immunotherapy to other cancer types is the genetic modification of T cells with antigen-specific receptors. In this article, we review strategies to redirect T cell specificity, including T cell receptor gene transfer and antibody receptor gene transfer.

Entities:  

Year:  2011        PMID: 22299059      PMCID: PMC3268993          DOI: 10.4161/self.2.2.15832

Source DB:  PubMed          Journal:  Self Nonself        ISSN: 1938-2030


  71 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

3.  Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

Authors:  Laurence J N Cooper; Zaid Al-Kadhimi; Lisa Marie Serrano; Timothy Pfeiffer; Simon Olivares; Adrian Castro; Wen-Chung Chang; Sergio Gonzalez; David Smith; Stephen J Forman; Michael C Jensen
Journal:  Blood       Date:  2004-10-26       Impact factor: 22.113

4.  Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.

Authors:  H M Finney; A D Lawson; C R Bebbington; A N Weir
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

5.  T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

Authors:  Maria R Parkhurst; James C Yang; Russell C Langan; Mark E Dudley; Debbie-Ann N Nathan; Steven A Feldman; Jeremy L Davis; Richard A Morgan; Maria J Merino; Richard M Sherry; Marybeth S Hughes; Udai S Kammula; Giao Q Phan; Ramona M Lim; Stephen A Wank; Nicholas P Restifo; Paul F Robbins; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-12-14       Impact factor: 11.454

6.  CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Authors:  Håkan Norell; Yi Zhang; James McCracken; Telma Martins da Palma; Aaron Lesher; Yueying Liu; Jeffrey J Roszkowski; Anquanette Temple; Glenda G Callender; Timothy Clay; Rimas Orentas; José Guevara-Patiño; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2010-01-06       Impact factor: 6.968

7.  Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.

Authors:  Qiangzhong Ma; Mazin Safar; Eric Holmes; Yawen Wang; Alton L Boynton; Richard P Junghans
Journal:  Prostate       Date:  2004-09-15       Impact factor: 4.104

Review 8.  Adoptive immunotherapy for posttransplantation viral infections.

Authors:  Catherine M Bollard; Ingrid Kuehnle; Ann Leen; Cliona M Rooney; Helen E Heslop
Journal:  Biol Blood Marrow Transplant       Date:  2004-03       Impact factor: 5.742

9.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

Authors:  H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

10.  Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.

Authors:  H E Heslop; C Y Ng; C Li; C A Smith; S K Loftin; R A Krance; M K Brenner; C M Rooney
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  8 in total

1.  In vivo imaging of T cells loaded with gold nanoparticles: a pilot study.

Authors:  Hui Li; Laura Diaz; Daniel Lee; Lei Cui; Xin Liang; Yingsheng Cheng
Journal:  Radiol Med       Date:  2013-12-06       Impact factor: 3.469

2.  Phototherapy using immunologically modified carbon nanotubes to potentiate checkpoint blockade for metastatic breast cancer.

Authors:  Yong Li; Xiaosong Li; Austin Doughty; Connor West; Lu Wang; Feifan Zhou; Robert E Nordquist; Wei R Chen
Journal:  Nanomedicine       Date:  2019-03-04       Impact factor: 5.307

3.  The inducible costimulator augments Tc17 cell responses to self and tumor tissue.

Authors:  Michelle H Nelson; Sreenath Kundimi; Jacob S Bowers; Carolyn E Rogers; Logan W Huff; Kristina M Schwartz; Krishnamurthy Thyagarajan; Elizabeth C Little; Shikhar Mehrotra; David J Cole; Mark P Rubinstein; Chrystal M Paulos
Journal:  J Immunol       Date:  2015-01-09       Impact factor: 5.422

Review 4.  Novel immunotherapies for hematologic malignancies.

Authors:  Michelle H Nelson; Chrystal M Paulos
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

Review 5.  Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.

Authors:  Kinga Majchrzak; Michelle H Nelson; Stefanie R Bailey; Jacob S Bowers; Xue-Zhong Yu; Mark P Rubinstein; Richard A Himes; Chrystal M Paulos
Journal:  Cancer Immunol Immunother       Date:  2016-01-29       Impact factor: 6.968

Review 6.  Th17 cells in cancer: the ultimate identity crisis.

Authors:  Stefanie R Bailey; Michelle H Nelson; Richard A Himes; Zihai Li; Shikhar Mehrotra; Chrystal M Paulos
Journal:  Front Immunol       Date:  2014-06-17       Impact factor: 7.561

Review 7.  NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer.

Authors:  Valentina Audrito; Antonella Managò; Federica Gaudino; Leonardo Sorci; Vincenzo Gianluca Messana; Nadia Raffaelli; Silvia Deaglio
Journal:  Front Immunol       Date:  2019-07-25       Impact factor: 7.561

8.  Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models.

Authors:  Ilenia Iaia; Loretta Gammaitoni; Giulia Cattaneo; Lidia Giraudo; Chiara Donini; Erika Fiorino; Luca Primo; Fabrizio Carnevale-Schianca; Massimo Aglietta; Alberto Puliafito; Dario Sangiolo
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.